Phase II study of the combination of pegylated liposomal doxorubicin and topotecan in platinum-resistant ovarian cancer

This publication has 12 references indexed in Scilit:

• Phase I trial of escalating doses of topotecan in combination with a fixed dose of pegylated liposomal doxorubicin in women with müllerian malignancies1
  Gynecologic Oncology, 2004
• Re: New Guidelines to Evaluate the Response to Treatment in Solid Tumors (Ovarian Cancer)
  JNCI: Journal of the National Cancer Institute, 2004
• Cancer Statistics, 2003
  CA: A Cancer Journal for Clinicians, 2003
• Pegylated liposomal doxorubicin (Caelyx™) in recurrent ovarian cancer
  Cancer Treatment Reviews, 2002
• Recurrent Epithelial Ovarian Carcinoma: A Randomized Phase III Study of Pegylated Liposomal Doxorubicin Versus Topotecan
  Journal of Clinical Oncology, 2001
• A Phase I Study of Liposomal Doxorubicin (Doxil) With Topotecan
  American Journal of Clinical Oncology, 2000
• Synergistic interactions of combinations of topotecan with standard drugs in primary cultures of human tumor cells from patients
  European Journal of Clinical Pharmacology, 1998
• Topotecan for the treatment of advanced epithelial ovarian cancer: an open-label phase II study in patients treated after prior chemotherapy that contained cisplatin or carboplatin and paclitaxel.
  Journal of Clinical Oncology, 1998
• Cyclophosphamide and Cisplatin Compared with Paclitaxel and Cisplatin in Patients with Stage III and Stage IV Ovarian Cancer
  New England Journal of Medicine, 1996
• Responses to salvage chemotherapy in ovarian cancer: a critical need for precise definitions of the treated population.
  Journal of Clinical Oncology, 1992